Merck Stock Up as Winrevair Meets Goal in Advanced PAH Study [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
MRK stock has declined 7% so far this year, compared to a 5.7% increase for the wider pharmaceutical industry. Register now to see our 7 Best Stocks for the Next 30 Days report - free today! Merck 's MRK phase III study called ZENITH evaluating its pulmonary arterial hypertension (“PAH”) drug, Winrevair (sotatercept), for more advanced disease, met its primary endpoint. The ZENITH study evaluated Winrevair, a novel activin signaling inhibitor, in patients with PAH, WHO Group 1 functional class (FC) III or IV at high risk of mortality. The study's primary endpoint was time to first morbidity or mortality event, which could be either all-cause death, lung transplantation, or PAH hospitalizations. Top-line data from the study showed that treatment with Winrevair added to background PAH therapy, leading to a statistically significant and clinically meaningful reduction in the risk of morbidity or mortality events compared to placebo. Based on the overwhelming efficacy seen in the
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Merck's ADC Drug Gets FDA Breakthrough Therapy Tag in NSCLC [Yahoo! Finance]Yahoo! Finance
- HSBC upgrades Merck stock to Buy on 2025 opportunities [Yahoo! Finance]Yahoo! Finance
- Merck & Co., Inc. (NYSE: MRK) was upgraded by analysts at HSBC Holdings plc from a "hold" rating to a "buy" rating. They now have a $130.00 price target on the stock.MarketBeat
- Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader [Yahoo! Finance]Yahoo! Finance
- TME Pharma Announces Corporate Strategy Update and Upcoming €2.6 Million Guaranteed Financing With Intention to Launch Public Offer Open Only to Shareholders to Enable Completion of Transactions Around NOX-A12 and NOX-E36 by June 2025 [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 10/31/24 - Beat
MRK
Sec Filings
- 11/22/24 - Form 8-K
- 11/6/24 - Form 10-Q
- 11/4/24 - Form 25-NSE
- MRK's page on the SEC website